Multi Center Clinical Trial Confirms FMTVDM© MPI in Seven Modern Clinical Laboratories in the USA and Asia. Artificial Intelligence (AI) with True Quantification

Richard M. Fleming1*, Matthew R. Fleming1, Andrew McKusick1 and Tapan K. Chaudhuri2

1The Camelot Foundation, FHHi-Omnific Imaging-Camelot, USA
2Nuclear Physician, Eastern Virginia Medical School, Norfolk, Virginia, US
*Corresponding author: Richard M. Fleming, The Camelot Foundation, FHHi-Omnific Imaging-Camelot, 707 East Grand Avenue, #8 El Segundo, CA 90245, USA, Tel: 818-210-6930; E-mail: mrmfd7@yahoo.com

Abstract

Background: The foundational work for nuclear cardiology began with Blumgart’s 1925 study of “circulation time.” The method was quantitative, yielding measurements of isotope change over time. The development of Myocardial Perfusion Imaging (MPI) resulted in qualitative images with clinician interpretation, yielding a 35% error rate when sensitivity and specificity were taken into account. The initial use of TI-201 was largely replaced by Tc-99m isotopes, which as others and we have now shown, like TI-201, redistribute albeit what was once thought to be slower than TI-201 is actually faster than TI-201.

Our initial work demonstrated that FMTVDM provides the first truly quantitative method removing human qualitative error, providing for the first truly quantitative Artificial Intelligence (AI) method for Nuclear Cardiology. This study looked at a multicenter study to determine FMTVDM© use in clinical laboratories.

Methods: Four hundred and one men and women between the ages of 21 and 85 years were studied in seven centers in the US. and Asia, using FMTVDM©. Results were compared to coronary angiography.

Using FMTVDM© redistribution measurements, percent diameter stenosis (%DSt) was calculated and using proprietary equations an Artificial Intelligence (AI) determination of the coronary flow reserve (“quantified/Fleming coronary flow reserve©” [QCFR/FCFR]) was determined and compared with the QCA derived measurements using best fit regression analysis.

Results: Each of the seven centers underwent training to familiarize them with FMTVDM© and implement its clinical use. Determination of the accuracy of the centers FMTVDM© measurements and implementation of the AI program was determined by comparing the final AI derived QCFR/FCFR with that obtained using QCA measured CFR. The resulting coefficient of determination 0.87582 (p<0.0001) demonstrated a “strong” relationship between the AI FMTVDM© method and QCA measured results.

Conclusion: FMTVDM© Al provides the first ever “quantified,” “enhanced” AI method for measuring coronary artery disease (CAD) beginning with the measurement of isotope redistribution and ending with the calculation of QCFR/FCFR© using the patented proprietary equations. This patented method is applicable to any device capable of measuring isotope activity over time including but not limited to hand-held probes, planar, SPECT and PET. This provides confirmation that clinical centers can be trained to implement the First Al “Truly Quantitative” Nuclear Cardiology method since its inception in 1925.

Keywords: FMTVDM©; “Stress-first/stress-only/stress-stress”; True quantification; Artificial intelligence (AI)

Background

The foundational work of nuclear cardiology began with Blumgart’s 1925 study of circulation time. Blumgart focused on quantitatively measuring isolate change over time. Since then Nuclear Cardiology has focused on qualitative image interpretation resulting in sensitivity and specificity issues. A demand for reducing patient radiation exposure has additionally resulted in a call for “stress-first/stress-only/stress-stress” imaging.

A preliminary VA study demonstrated FMTVDM© “stress-stress” imaging statistically out performed conventional two-injection MPI “stress-rest” approach, while lowering patient mSv radiation exposure [1-15] with FMTVDM© resulting in statistically improved clinical outcomes, providing the only True Quantitative AI method [16-18] removing the qualitative errors made using “stress-rest” MPI methods [19,20], and reducing the amount of patient exposure during MPI as seen in Figure 1. This study examined the ability to implement FMTVDM© in seven different centers in the USA and Asia.
Figure 1: Patient exposure is defined in millisieverts (mSv), which is defined as the biological effect of radiation. One Sievert (S) is the International Standard (IS) equaling the effect of one joule of X-rays per kilogram of patient body mass. A variety of medical studies are shown in the upper panel, while more Cardiac specific studies are displayed in the bottom panel. FMTVDM® shown as FHRWW® yielded 3.75 mSv per study (less than Coronary CT or CT Angiography) while conventional studies using 2-injections of isotope yield between 8 and 25 mSv patient exposure, depending upon the isotope and dose used. As seen in the top panel, the 2 injection approaches and Coronary CT/Angiography provide more radiation exposure than the annual background radiation. 5-mSv is frequently considered the standard accepted limit, below which the risk of inducing cancer is considered minimal.

Materials and Methods

FMTVDM®

Following the protocol detailed in FMTVDM® 401 men and women were studied as detailed previously [15] at seven different Centers-of-Excellence (COE).

Coronary arteriograms

Following standard procedures previously detailed [10-14] coronary angiography was performed, %DS and QCA results were obtained. Initial visual reporting of percent diameter stenosis (%DS) was determined only after clinicians had undergone extensive training necessary to reduce the qualitative errors [21].

Calculation of %DS from isotope redistribution

The derived isotope redistribution was then calculated using pixel-by-pixel isotope measurement to determine redistribution wash-in (initial delay in isotope uptake) as described previously [4-7] and redistribution washout (failure to retain isotope) or expected (normal) redistribution as shown in Figure 2.

Calculation of Quadratic/Fleming Coronary Flow Reserve (QCFR®, FCFR®) from Isotope Redistribution determined %DS. The AI proprietary equations and process derived from measured human coronary artery analysis [10-14] followed the FMTVDM® protocol (p=3.8 x 10^-8) directly introducing those measurements into proprietary equations protected by patent #9566037 automatically deriving CFR. The measurements and subsequent derivation of CFR (QCFR/FCFR) were done at multiple times and are NOT dependent on isotope, camera type (SPECT, PET), camera company or operator availability.

Statistical analysis

Comparison of FMTVDM® measured/quantified isotope redistribution and subsequent AI calculated Quadratic/Fleming Coronary Flow Reserve (QCFR®, aka. FCFR®) Using the FMTVDM® and proprietary equations (QCFR®, aka. FCFR®). 401 individuals were studied and the AI quantified results from the FMTVDM® Proprietary equations derived (QCFR®/FCFR®) were compared with QCA derived outcomes. Residual plots were analyzed for data bias. The comparison of QCFR® (aka FCFR®) derived from the FMTVDM® with QCA measured CFR was performed using regression analysis and best fit linear regression modeling.

Citation: Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) Multi Center Clinical Trial Confirms FMTVDM® MPI in Seven Modern Clinical Laboratories in the USA and Asia. Artificial Intelligence (AI) with True Quantification. J Nucl Med Radiat Ther 9: 372. doi:10.4172/2155-9619.1000372
Results

Following assessment of each clinical facility to determine adequately trained personnel, operators at 7-Centers of Excellence (COE) were recruited to conduct “stress-first/stress only/stress-stress” FMTVDM Imaging. Outcomes were independent of isotope, camera type, Company Camera or “stressor” employed. Outcome analysis was obtained using AI measured and quantitatively derived CFR (QCFR©/FCFR©) results using FMTVDM©/ measurements and proprietary equations, compared with that obtained from direct QCA. The results from the 7COE yielded regression analysis of $y=(0.8758•x)+0.4291$, where $y$=the QCFR and $x$=the QCA measured CFR. The R2 value 0.87582 demonstrated the 7-COE accurately, consistently and reproducibly clinically implemented FMTVDM© to derive by AI, QCFR©/FCFR© in all 401 patients.

Discussion

The first step in the demonstration of a new method for diagnostically studying a health problem is to compare the new test with the currently accepted approach [4-7]. If the results are promising investigators conduct a single center clinical trial [15]. If the newer method provides better clinical and diagnostic outcomes than the currently accepted method [4-7,15] and provides a significant advancement for the field [16-20], a multicenter trial is initiated to demonstrate that clinicians with various backgrounds, in various clinical settings are able to accurately, consistently and reproducibly utilize the new diagnostic test and obtain the expected outcomes.

In this study, seven COE from the USA and Asia independently conducted clinical MPI studies using FMTVDM© using the first true quantification method for nuclear imaging studies and AI. The outcomes demonstrated the ability of each COE to accurately, consistently and reproducibly use FMTVDM© to diagnose the level of clinical disease without error, while saving time, reducing healthcare costs and markedly decreasing patient radiation exposure with potential associated risks.

Conclusions

FMTVDM© utilizing AI accurately, consistently and reproducibly provided true quantification of CAD in 7-COE in the USA and Asia. The utilization of AI FMTVDM© provided accurate, consistent and reproducible quantitative CFR beginning with the true quantification of isotope redistribution using the patented proprietary equations independent of isotope, camera type (SPECT, PET), camera company, operator variables or site location. FMTVDM© provides the first truly quantitative, truly AI Nuclear Imaging of CAD and CFR introducing a new era of nuclear cardiology. The use of FMTVDM© provides the first ever “Quantitative” AI method able to differentiate tissue vascularity and metabolism and as such provides an evolutionary quantum leap forward for the fields of nuclear cardiology and nuclear medicine.

Comparison of 99mTc Sestamibi with thallium reinjection and [18F] fluoro-deoxy-glucose. Circulation 89: 578-587.

Sheikine Y, Berman DS, Di Carli ME (2010) Technetium-99m-sestamibi redistribution after exercise stress test identified by a novel cardiac gamma camera: Two case reports. Clin Cardiol 33: e39-e45.

Fleming RM, Harrington GM, Baqir R, Jay S, Challapalli S, et al. (2009) The evolution of nuclear cardiology takes us back to the beginning to develop today’s “new standard of care” for cardiac imaging: How quantifying regional radioactive counts at 5 and 60 minutes post-stress unmask hidden ischemia. Methodist Debakey Cardiovasc J 5: 42-48.

Fleming RM, Harrington GM, Baqir R, Jay S, Challapalli S, et al. (2010) Renewed application of an old method improves detection of coronary ischemia. A higher standard of care. Federal Practitioner 27: 22-31.

Fleming RM, Harrington GM. FHRRW stress SPECT protocol reduces radioactive dosage and increases ischemia detection. ANZ Nuclear Medicine 2010;41: 24-232.

Fleming RM, Harrington GM, Kearney DS, Tomsho M, Shels J (2012) Myoview redistribution, stress once – image twice protocol improves detection of ischemia in addition to improving patient throughput and reducing patient radiation to 3.75 mSv. J Nucl Med 53: 1831.

Gould KL, Lipscomb K, Hamilton GW (1974) Physiologic basis for assessing critical coronary stenosis. Amer J Cardiol 33: 87-94.

Brown BG (1985) Response of normal and diseased epicardial coronary arteries to vasoactive drugs: Quantitative arteriographic studies. Amer J Cardiol 56: 23e-29e.

Fleming RM, Kirkeeide RL, Taegtmeyer H, Adyanthaya A, Cassidy DB, et al. (1991) A comparison of technetium 99-m Teboroxime tomography to automated quantitative coronary arteriography and thallium - 201 spect. J Am Coll Cardiol 17: 1297-1302.

Fleming RM, Kirkeeide RL, Smalling RW, Gould KL (1991) Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol 18: 945-951.

Fleming RM, Gibbs HR, Swafford J (1992) Using quantitative coronary arteriography to redefine spect sensitivity and specificity. Am J Physiol Imaging 7: 59-65.

Fleming RM, Harrington GM (1994) Quantitative coronary arteriography and its assessment of atherosclerosis. part I. Examining the independent variables. Angiology 45: 829-833.

Fleming RM, Harrington GM (1994) Quantitative coronary arteriography and its assessment of atherosclerosis. Part II. Calculating stenosis flow reserve directly from percent diameter stenosis. Angiology 45: 835-840.

Fleming RM, Fleming MR, Harrington G, McKusick A, Chaudhuri T (2018) USVHA Study demonstrates statistically significant improvement in diagnosis and care of U.S. Veterans using FMTVDM© HFRWW © "Quantitative" Nuclear Imaging. The era of truly quantitative stress-first, stress-only imaging has begun! J Nucl Med Radiat Ther 9: S9-006

Fleming RM, Fleming MR, McKusick A, Chaudhuri T (2018) FMTVDM®- TFM©®. True quantification requires standardization of the tool being used to measure, with a known, unchanging standard to produce accurate, consistent and reproducible quantified measurements. J Nucl Cardiol 19: 23

Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) Semi-quantification limitations: FMTVDM© demonstrates quantified tumor response to treatment with both regional blood flow and metabolic changes. J Nucl Med

Fleming RM, Fleming MR, Dooley WC, Sheikh A, McKusick A, et al. (2018) FMTVDM© HFRWW ® & B.R.S.T. The FIRST TRUE “Quantitative” Nuclear Imaging Protocols with Proprietary Equations following The Fleming Method (TFM) for Nuclear Scintillation Equipment Quantitative Standardization. Biomed J Sci and Tech Res 4: 1-4

Fleming RM, Fleming MR, McKusick A, Chaudhuri TK, Dooley WC, et al. (2018) FMTVDM© stress-first/stress-only imaging is here! But first we need to clarify the use of what (1) Stress, (2) rest, (3) redistribution and (4) quantification, really mean. J Nucl Med Radiat Ther 9: 39-005.

References

1. Franceschi M, Guimond J, Zimmerman RE, Picard MV, English RJ, et al. (1990) Myocardial clearance of Tc-99m hexisid-2-methoxy-2-methylpropyl isonitrile (MIBI) in patients with coronary artery disease. Clin Nucl Med 15: 307-312.

2. Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, et al. (1994) Myocardial viability in patients with chronic coronary artery disease.
20. Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) Multi Center Clinical Trial Confirms FMTVDM® MPI in Seven Modern Clinical Laboratories in the USA and Asia. Artificial Intelligence (AI) with True Quantification. J Nucl Med Radiat Ther 9: 372. doi:10.4172/2155-9619.1000372

21. Fleming RM, Gaede, R (1996) Teaching physicians and health care providers to accurately read coronary arteriograms. Angiology 47: 349-359.